DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
DexCom
DXCM
Hutchmed (China)
HCM
New Fortress Energy
NFE
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
SUPN Supernus Pharmaceuticals
- 39.110
- -0.420-1.06%
Close Feb 14 16:00 ET
- 39.110
- 0.0000.00%
Post 16:20 ET
2.16BMarket Cap36.65P/E (TTM)
39.590High38.980Low331.09KVolume39.590Open39.530Pre Close12.98MTurnover0.69%Turnover Ratio1955.50P/E (Static)55.22MShares40.28052wk High2.14P/B1.87BFloat Cap25.53052wk Low--Dividend TTM47.71MShs Float61.250Historical High--Div YieldTTM1.54%Amplitude4.300Historical Low39.217Avg Price1Lot Size
Supernus Pharmaceuticals Stock Forum
February 4, 2025 at 9:00 AM EST ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion device that provides continuous treatment during the waking day for more consistent control of OFF timeONAPGO will be available in the U.S. in second quarter 2025
Supernus Pharmaceuticals 3Q Rev $175.7M
Supernus Resubmits New Drug Application for Parkinson's Treatment Device
Supernus Pharmaceuticals resubmitted its new-drug application for a device to treat patients with Parkinson's disease to the Food and Drug Administration.
The Rockville, Md. biopharmaceutical company said on Thursday it believes it has addressed the questions in an April letter from the FDA about the review of its SPN-830 apomorphine-infusion device to treat "off" episodes in Parkinso...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Supernus Pharmaceuticals (SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech (LEGN.US)$ & $Johnson & Johnson (JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio (TSVT.US)$ & $Bristol-Myers Squibb (BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals (VNDA.US)$...
waiting patiently for fda 😌🙏
$Akebia Therapeutics (AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co (MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals (REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca (AZN.US)$ : 🤔
⇒...
$Vanda Pharmaceuticals (VNDA.US)$ $Legend Biotech (LEGN.US)$ $Supernus Pharmaceuticals (SUPN.US)$ $ImmunityBio (IBRX.US)$ $Aquestive Therapeutics (AQST.US)$ $X4 Pharmaceuticals (XFOR.US)$ $Liquidia (LQDA.US)$ $Neurocrine Biosciences (NBIX.US)$ $Moderna (MRNA.US)$ $Day One Biopharmaceuticals (DAWN.US)$
...
No comment yet